From GlobeNewswire: 2025-04-18 08:30:00

The global Prostate Cancer Diagnostics Market, valued at USD 8.57 billion in 2023, is projected to reach USD 15.09 billion by 2032, with a CAGR of 6.5%. Factors driving growth include rising cancer prevalence, increased awareness, advanced diagnostic methods, and government-funded screening programs.

The United States Prostate Cancer Diagnostics Market was USD 0.96 billion in 2023, expected to reach USD 1.26 billion by 2032. The U.S. contributes significantly to the global market due to routine screenings, advanced healthcare facilities, and a high incidence of prostate cancer cases.

Confirmatory Tests accounted for 65% of the market share in 2023, dominating the Prostate Cancer Diagnostics Market. These tests, including biopsies and imaging tests, provide accurate diagnosis after initial screening, driving revenue growth. Personalized treatment plans and targeted therapies fuel the demand for accurate diagnostic confirmation.

The Adenocarcinoma segment held the largest share of the global Prostate Cancer Diagnostics Market in 2023, driven by its common occurrence and demand for diagnosis. PSA testing, multiparametric MRI, and biopsy are key in diagnosing this type of cancer. Public health campaigns and AI-based diagnostic platforms are boosting segment growth.

Outpatient Facilities led market revenue in 2023, offering convenience, cost-effectiveness, and advanced diagnostic tools. These facilities provide PSA tests, imaging services, and biopsies without hospital admission, attracting health-conscious patients. Digital platforms and telemedicine enhance the diagnostic process, making outpatient care more appealing. Outpatient diagnostic clinics are increasingly popular for prostate cancer testing among men over 50 due to rising health awareness. The market segmentation includes test types like PSA and confirmatory tests, types of cancer, and end users like hospitals and outpatient facilities. In North America, early adoption and key players drive market growth, while Europe and Asia Pacific show promising trends.

Recent developments include Exact Sciences launching a more accurate Genomic Prostate Score test and Myriad Genetics upgrading its Prolaris test for better prognosis evaluation of prostate cancer. The market report covers various segments like test types, types of cancer, end users, regional analysis, and company profiles, providing valuable insights for stakeholders in the industry.

SNS Insider is a leading market research and consulting agency providing clients with current and accurate market data, consumer insights, and opinions to make informed decisions in a changing market landscape. Their research methods include surveys, video talks, and focus groups to offer valuable insights for businesses in the healthcare industry.



Read more at GlobeNewswire: Prostate Cancer Diagnostics Market Size to Hit USD 15.09